Great Britain has approved Pfizer‘s COVID-19 pill for patients over the age of 18 years who have mild to moderate infection and are at high risk of their illness worsening.
The approval comes as the country scrambles to build its defenses amid a record hit a daily record of new COVID-19 cases on Thursday, government data showed surge in COVID-19 cases.
Based on data, the pill, Paxlovid, is most effective when taken during the early stages of COVID-19, Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) said on Friday, recommending that the drug be used within five days of the onset of symptoms.
Pfizer this month said Paxlovid showed near 90 per cent efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.
“We now have a further antiviral medicine for the treatment of COVID-19 that can be taken by mouth rather than administered intravenously. This means it can be administered outside a hospital setting,” MHRA chief June Raine said in a statement.
- Dual UK-Iranian national released on bail over suspected plot against US-run military base
- Europe to release reserve oil and diesel after threats from Trump
- As Texas declares state of emergency over fuel shortage, what’s dyed diesel
- U.S. reportedly threatens EU diesel export ban unless reserve fuel released
-
![]()
G7 to release 100M barrels of diesel and crude -
![]()
U.S., Saudi Arabia investigate after FlyDubai captain attacked by copilot on Israel-bound flight -
![]()
Wall Street Journal reporter releases memoir, recounts fear he faced in Russian prison -
![]()
Indian airline captain hailed as hero after cockpit attack on Flydubai flight
Canadian health regulators continue to review the treatment for use in the country.
Comments
Want to discuss? Please read our Commenting Policy first.